Correction to 'Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study'
- PMID: 40650473
- PMCID: PMC12587355
- DOI: 10.1111/jdv.20829
Correction to 'Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study'
Figures
Erratum for
-
Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study.J Eur Acad Dermatol Venereol. 2025 Jun;39(6):1152-1162. doi: 10.1111/jdv.20526. Epub 2025 Jan 23. J Eur Acad Dermatol Venereol. 2025. PMID: 39846397 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
